Aemetis, Inc. (NASDAQ:AMTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Aemetis, Inc. (NASDAQ:AMTX) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $12.95.

AMTX has been the subject of a number of recent analyst reports. UBS Group lowered their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a research report on Monday, August 19th. StockNews.com upgraded Aemetis to a “sell” rating in a report on Wednesday, July 31st. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Aemetis in a report on Friday, August 2nd. Ascendiant Capital Markets lowered their target price on shares of Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Finally, Truist Financial reaffirmed a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st.

Aemetis Stock Performance

Aemetis stock opened at $3.00 on Wednesday. The stock has a market cap of $133.19 million, a PE ratio of -2.56 and a beta of 1.24. The stock has a 50-day moving average price of $2.55 and a 200 day moving average price of $3.18. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03.

Aemetis (NASDAQ:AMTX) last posted its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25). The firm had revenue of $66.56 million for the quarter, compared to analyst estimates of $75.37 million. During the same period in the previous year, the company posted ($0.68) earnings per share. On average, equities analysts predict that Aemetis will post -2.07 EPS for the current year.

Institutional Trading of Aemetis

Institutional investors have recently modified their holdings of the company. Susquehanna Fundamental Investments LLC increased its holdings in Aemetis by 287.4% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock valued at $379,000 after purchasing an additional 93,536 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Aemetis in the second quarter worth about $306,000. Rhumbline Advisers grew its stake in shares of Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares in the last quarter. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis during the 2nd quarter valued at about $70,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis during the 1st quarter valued at about $84,000. Hedge funds and other institutional investors own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.